Immunotherapy is one of the most exciting areas of oncology drug development. Numerous manufacturers and investors are entering the field and are rapidly expanding and diversifying their portfolios…
The availability of novel disease-modifying therapies (DMTs)—Copaxone 40 mg three times weekly (3TW), Plegridy, Lemtrada, oral DMTs—has complicated clinical decision-making and treatment choice…
Last Updated 15 October 2015 The type 2 diabetes therapy market will rapidly expand over our 2014-2024 study period, fueled by the disease’s increasing prevalence and a high unmet need for drugs…
Over the next ten years, more than 15 million men worldwide Despite the tremendous potential of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, limited market access will…
By definition, rare diseases affect relatively few individual patients, but as a group they encompass up to 8,000 recognized rare diseases affecting approximately 10% of the U.S. population. The…
Outpatient parenteral antimicrobial therapy (OPAT) allows patients with clinically stable infections (e.g., skin and soft tissue infections, bone and joint infections, osteomyelitis, intra-…
Glaucoma refers to a group of chronic, progressive eye diseases caused primarily by elevated intraocular pressure (IOP), which left untreated can lead to damage of the optic nerve and eventual…
The availability of novel disease-modifying therapies (DMTs)—oral DMTs, Plegridy, and Lemtrada—has complicated clinical decision making and treatment choice in the management of multiple…
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neurone disease (MND), is a degenerative disorder of the nervous system characterized by progressive muscle…
The symptomology of Parkinson’s disease (PD) is heterogeneous; individual patients experience different combinations of primary motor symptoms, complications of therapy, and/or key nonmotor…
Osteoporosis is a common bone disease estimated to have affected 24.5 million U.S. patients in 2014, although owing to the asymptomatic nature of osteoporosis, the disease remains underdiagnosed. U…
Last Updated 2 October 2015 A new era in the market for multiple sclerosis (MS) disease-modifying therapies (DMTs) has dawned: Novartis/Mitsubishi Tanabe Pharma’s fingolimod (Gilenya/Imusera) and…
How Will Physician and Payer Attitudes and Decisions Shape this Market? The treatment of metastatic colorectal cancer (mCRC) is increasingly driven by patients’ RAS mutational status of their…
How Will Healthcare Reform and Payer-Led Cost-Containment Strategies Impact U.S. Prescribing? The market opportunity for hepatitis C virus (HCV) features a large prevalent population, a…
Juvenile idiopathic arthritis (JIA) is an autoimmune, rheumatologic disease characterized by joint inflammation, pain, and stiffness. JIA encompasses multiple forms of chronic arthritis in children…